Published in PLoS One on October 17, 2014
Development of a new model system to dissect isoform specific Akt signalling in adipocytes. Biochem J (2015) 1.41
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia (2016) 0.82
Foxc2 enhances proliferation and inhibits apoptosis through activating Akt/mTORC1 signaling pathway in mouse preadipocytes. J Lipid Res (2015) 0.81
Calorie restriction leads to greater Akt2 activity and glucose uptake by insulin-stimulated skeletal muscle from old rats. Am J Physiol Regul Integr Comp Physiol (2016) 0.78
Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines. PLoS One (2015) 0.75
Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition. Oncogene (2016) 0.75
MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res (2004) 168.89
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 64.61
Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics (2009) 31.84
The Jalview Java alignment editor. Bioinformatics (2004) 21.74
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng (1995) 19.22
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model (2011) 6.49
Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des (2002) 5.65
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des (2001) 4.54
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci (2004) 4.40
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J (2005) 3.58
Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell (2002) 3.53
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett (2005) 3.50
Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem (2003) 2.87
The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. Proc Natl Acad Sci U S A (2007) 2.65
The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab (2011) 2.06
Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs (2010) 2.01
Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene (2006) 1.72
The PKB/AKT pathway in cancer. Curr Pharm Des (2010) 1.67
Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One (2010) 1.62
Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J Biol Chem (2008) 1.55
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia (2011) 1.45
The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia (2011) 1.43
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther (2011) 1.33
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia (2012) 1.16
The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood (2011) 1.12
Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes. Biochem J (2011) 1.10
Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma. Laryngoscope (2011) 1.09
A path planning approach for computing large-amplitude motions of flexible molecules. Bioinformatics (2005) 1.04
Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One (2012) 1.03
MoMA-LigPath: a web server to simulate protein-ligand unbinding. Nucleic Acids Res (2013) 0.84
A spectroscopic investigation into the interactions of 3'-O-carboxy esters of thymidine with bovine serum albumin. Biopolymers (2009) 0.80
Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB. Mini Rev Med Chem (2011) 0.78
Insight into the structural mechanism for PKBα allosteric inhibition by molecular dynamics simulations and free energy calculations. J Mol Graph Model (2013) 0.78
Elucidating the binding efficacy of β-galactosidase on graphene by docking approach and its potential application in galacto-oligosaccharide production. Bioprocess Biosyst Eng (2016) 1.10
Anticancer compound plumbagin and its molecular targets: a structural insight into the inhibitory mechanisms using computational approaches. PLoS One (2014) 0.80
Relaxin: a hormonal aid to diagnose pregnancy status in wild mammalian species. Theriogenology (2014) 0.79
Endocrine Disruption: Computational Perspectives on Human Sex Hormone-Binding Globulin and Phthalate Plasticizers. PLoS One (2016) 0.77
Endocrine disruption: In silico interactions between phthalate plasticizers and corticosteroid binding globulin. J Appl Toxicol (2017) 0.75
Assessment of IL-18 Serum Level and its Promoter Polymorphisms in the Saudi Coronary Artery Disease (CAD) Patients. J Cell Biochem (2017) 0.75